Business Description
ISIN : US0367521038
Total Employee Number:
97,100Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 3.52 | |||||
Interest Coverage | 5.08 | |||||
Piotroski F-Score | 4/9 | |||||
Beneish M-Score | -3.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.2 | |||||
3-Year EBITDA Growth Rate | 1 | |||||
3-Year EPS without NRI Growth Rate | 1.4 | |||||
3-Year FCF Growth Rate | -22.1 | |||||
3-Year Book Growth Rate | 9.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.43 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.68 | |||||
9-Day RSI | 53.6 | |||||
14-Day RSI | 52.44 | |||||
3-1 Month Momentum % | -3.53 | |||||
6-1 Month Momentum % | 11.46 | |||||
12-1 Month Momentum % | 23.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.75 | |||||
Dividend Payout Ratio | 0.23 | |||||
3-Year Dividend Growth Rate | 10.1 | |||||
Forward Dividend Yield % | 1.76 | |||||
5-Year Yield-on-Cost % | 3.18 | |||||
3-Year Average Share Buyback Ratio | 2.5 | |||||
Shareholder Yield % | 2.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Net Margin % | 2.47 | |||||
EBITDA Margin % | 4.38 | |||||
FCF Margin % | 3.13 | |||||
OCF Margin % | 3.71 | |||||
ROE % | 11.26 | |||||
ROA % | 4.01 | |||||
ROIC % | 6.66 | |||||
3-Year ROIIC % | 1.91 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 17.61 | |||||
Forward PE Ratio | 14.6 | |||||
PE Ratio without NRI | 13.48 | |||||
Shiller PE Ratio | 16.19 | |||||
Price-to-Owner-Earnings | 13.01 | |||||
PEG Ratio | 2.54 | |||||
PS Ratio | 0.44 | |||||
PB Ratio | 1.91 | |||||
Price-to-Tangible-Book | 15.45 | |||||
Price-to-Free-Cash-Flow | 13.87 | |||||
Price-to-Operating-Cash-Flow | 11.69 | |||||
EV-to-EBIT | 14.64 | |||||
EV-to-Forward-EBIT | 14.86 | |||||
EV-to-EBITDA | 12.13 | |||||
EV-to-Forward-EBITDA | 12.53 | |||||
EV-to-Revenue | 0.53 | |||||
EV-to-Forward-Revenue | 0.54 | |||||
EV-to-FCF | 17 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 0.7 | |||||
Price-to-DCF (Earnings Based) | 0.65 | |||||
Price-to-DCF (FCF Based) | 1.01 | |||||
Price-to-Median-PS-Value | 0.63 | |||||
Price-to-Graham-Number | 3.04 | |||||
Earnings Yield (Greenblatt) % | 6.83 | |||||
FCF Yield % | 7.32 | |||||
Forward Rate of Return (Yacktman) % | 9.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:ELV
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Elevance Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 201,113 | ||
| EPS (TTM) ($) | 22.5 | ||
| Beta | 0.8393 | ||
| 3-Year Sharpe Ratio | -0.21 | ||
| 3-Year Sortino Ratio | -0.28 | ||
| Volatility % | 34.44 | ||
| 14-Day RSI | 52.44 | ||
| 14-Day ATR ($) | 10.862726 | ||
| 20-Day SMA ($) | 388.8295 | ||
| 12-1 Month Momentum % | 23.3 | ||
| 52-Week Range ($) | 274.84 - 436.24 | ||
| Shares Outstanding (Mil) | 216.87 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elevance Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elevance Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-05 | In 168 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-01-28 08:30 | In 161 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-28 06:00 | In 161 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-21 08:30 | In 62 days | ||
| Third quarter earnings results for 2026 | 2026-10-21 06:00 | In 62 days | ||
| USD 1.720000 Cash Dividend | 2026-09-10 | In 20 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-15 08:30 | 426.79 (-2.17%) | ||
| Second quarter earnings results for 2026 | 2026-07-15 06:00 | 426.79 (-2.17%) | ||
| USD 1.720000 Cash Dividend | 2026-06-10 | 424.43 (+1.01%) | ||
| General meeting for 2026 | 2026-05-13 08:00 | 393.30 (+2.84%) |
Elevance Health Inc Frequently Asked Questions
Guru Commentaries on NYSE:ELV
We have owned Elevance for several years. Like UnitedHealth Group, their government sponsored plans including Medicaid, Medicare Advantage (MA), and the ACA Health Exchanges have faced margin pressure driven by the post-Covid hangover. Elevance is adjusting to this post-Covid environment, and we believe that its earnings should return to double-digit growth next year. Similar to UnitedHealth Group, 'Mr. Market' is beginning to recognize that Elevance’s fundamentals remain strong and its discounted shares are beginning to recover.
Shares of Elevance Health, the health insurer and healthcare-services provider formerly known as Anthem, rallied during the quarter as margins expanded—after a protracted decline—due to declining medical costs, stronger pricing and increased utilization with higher premiums.
Press Release
Articles on Elevance Health Inc
Headlines
See More- 1
- 1




